Aligos Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALGS Nasdaq 8731 https://www.aligos.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aligos Therapeutics Inc

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference - May 23rd, 2022 8:05 pm
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results - May 4th, 2022 8:05 pm
Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022 - May 3rd, 2022 12:00 pm
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022 - Apr 27th, 2022 8:05 pm
Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision - Apr 5th, 2022 1:25 pm
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development - Apr 4th, 2022 12:00 pm
After patient hospitalized, Peninsula drug developer stops 2nd chronic hepatitis B program this year - Mar 22nd, 2022 3:09 pm
Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio - Mar 22nd, 2022 12:00 pm
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights - Mar 10th, 2022 9:05 pm
Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022 - Mar 2nd, 2022 9:05 pm
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes - Feb 11th, 2022 12:00 pm
Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference - Feb 3rd, 2022 9:05 pm
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401) - Jan 26th, 2022 1:00 pm
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully - Jan 18th, 2022 9:21 am
Biotech's virtual JPM conference was a big deal. But, actually, there wasn't one - Jan 14th, 2022 9:51 pm
10 Biotech Stocks To Buy According To Chinese Billionaire Lei Zhang - Jan 12th, 2022 2:31 pm
Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH - Jan 11th, 2022 2:12 pm
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt - Jan 7th, 2022 5:24 pm
Why Aligos Therapeutics Stock Crumbled Today - Jan 6th, 2022 11:21 pm
Peninsula biotech sheds half its value, ditches hepatitis B program after clinical failure - Jan 6th, 2022 10:53 pm